A Phase 2 interventional study of Iparomlimab and Tuvonralimab and Paclitaxel in HR-positive/HER2-negative Breast Cancer, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by RenJi Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Breast Neoplasms by RenJi Hospital — 15 open to participants now, 17 under way, 2 of them phase 3. Breast Neoplasms · RenJi Hospital.
Among the 20 studies in Breast Neoplasms by RenJi Hospital, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 8 of the 16 other live ones, and was the 20th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →15 of the 20 studies in Breast Neoplasms by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:
RenJi Hospital · Sites in China
Ages 18–70 · Women only
RenJi Hospital · Sites in China
Ages 18–75 · Women only
RenJi Hospital · Sites in China
Ages 18+
RenJi Hospital · Sites in China
RenJi Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 2
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 143 across the 13 interventional studies, 172 across the 7 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
7 of the studies in Breast Neoplasms by RenJi Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06715826RenJi HospitalTarget-specific immunoPET Imaging of Breast Cancer | 2026-11 |
| NCT05831878RenJi HospitalRC48-ADC in HER2-low Advanced Breast Cancer | 2026-12 |
| NCT07396324RenJi HospitalNeoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer | 2026-12 |
| NCT07283692RenJi HospitalNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) | 2026-12 |
| NCT06301438RenJi HospitalDalpiciclib in HR+/HER2- ABC | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 20 studies in Breast Neoplasms by RenJi Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Iparomlimab and Tuvonralimab (QL1706) in combination with weekly paclitaxel and carboplatin as neoadjuvant therapy
Drug: Iparomlimab and Tuvonralimab · Drug: Paclitaxel · Drug: Carboplatin
Drug pages: IparomlimabStudies of IparomlimabIparomlimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TuvonralimabStudies of TuvonralimabTuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
5.0mg/kg qw, start from C1D15
Also known as: QL1706
80mg/m\^2 qw
Also known as: PTX
AUC=1.5, D1, 8, 15, every 28 days
Also known as: CBP
Proportion of patients with pCR
Number of patients with pathological complete response/Number of all eligible patients
Time frame: 1-2 weeks after surgery
Proportion of patients with adverse events
Number of patients with adverse events during neoadjuvant therapy assessed according to the NCI CTCAE v5.0/Number of all eligible patients
Time frame: From the date of starting neoadjuvant therapy to the end of the treatment (up to approximately 1 year)
Plan to share: Yes — Study protocol, SAP and ICF are to be shared with other researchers.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: starting 6 months after publication
Access criteria: IPD can be accessed from the corresponding author on reasonable request
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 7 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iparomlimab · Tuvonralimab